Liquid Ventilation by Qutaiba A.   Tawfic
Oman Medical Specialty Board
Liquid Ventilation
Qutaiba A. Tawfic, Rajini Kausalya
Qutaiba A. Tawfic  ,  Rajini Kausalya 
Department of Anesthesiology and Intensive Care, Sultan Qaboos, University 
Hospital, Muscat, Sultanate of Oman.
E-mail: drqutaibaamir@yahoo.com
Received: 14 Aug 2010 / Accepted: 23 Nov 2010
© OMSB, 2011
Oman Medical Journal (2011) Vol. 26, No. 1: 4-9
DOI 10. 5001/omj.2011.02
Review Article
Abstract
Mammals  have  lungs  to  breathe  air  and  they  have  no  gills  to 
breath  liquids.  When  the  surface  tension  at  the  air-liquid 
interface of the lung increases, as in acute lung injury, scientists 
started to think about filling the lung with fluid instead of air 
to  reduce  the  surface  tension  and  facilitate  ventilation.  Liquid 
ventilation (LV) is a technique of mechanical ventilation in which 
the lungs are insufflated with an oxygenated perfluorochemical 
liquid  rather  than  an  oxygen-containing  gas  mixture.  The  use 
of perfluorochemicals, rather than nitrogen, as the inert carrier 
of  oxygen  and  carbon  dioxide  offers  a  number  of  theoretical 
advantages for the treatment of acute lung injury. In addition, 
there are non-respiratory applications with expanding potential 
including  pulmonary  drug  delivery  and  radiographic  imaging. 
The potential for multiple clinical applications for liquid-assisted 
ventilation will be clarified and optimized in future.
Keywords:  Liquid  ventilation,  perfluorochemicals,  perfluoro-
carbon, respiratory distress, surfactant.
Introduction
Liquid-assisted ventilation, as an alternative ventilation strategy 
for  respiratory  distress,  is  progressing  from  theory  and  basic 
science research to clinical application.1 The potential use of liquid 
ventilation (LV) has been investigated since 1962 when Kylstra 
evaluated the ability to sustain gas exchange in mice spontaneously 
breathing saline oxygenated at 6 atmospheres.2 Clark subsequently 
demonstrated  that  spontaneously  breathing  mice  could  survive 
when submerged in perfluorocarbons (PFCs) under normobaric 
conditions.3 The first trial of liquid ventilation in preterm neonates 
in 1989 showed the feasibility and potential of liquid ventilation 
in humans.4 Relatively few agents have the properties of carrying 
O2 and CO2– essentially only silicone oils and perfluorocarbons 
(PFCs).  Silicone  oils  found  to  be  toxic,  and  hence  only  PFCs 
remained  for  possible  use.5  PFCs  were  synthesized  during  the 
development of the atomic bomb (the Manhattan Project) where 
they were given the code name ‘Joe’s stuff.’3 Over the last 40 years, 
liquid  ventilation  has  been  studied  in  various  animal  models: 
normal, premature and with lung injury.1-3,5
Two primary techniques for liquid-assisted ventilation have 
emerged; total liquid ventilation and partial liquid ventilation.1 
While  total  liquid  ventilation  remains  as  an  experimental 
technique, partial liquid ventilation could be readily applied, but 
its implementation in clinical practice awaits results from ongoing 
and future clinical trials that may define its effectiveness.6
The PFC liquids used to support pulmonary gas exchange are 
a type of synthetic liquid fluorinated hydrocarbon (hydrocarbons 
with the hydrogen replaced by fluorine, and for perflubron where 
a bromine atom is added as well) with high solubility for oxygen 
and carbon dioxide.3 These are chemically and biologically inert, 
clear  and  odorless,  have  low  surface  tension,  and  undergo  no 
metabolism in kidneys or liver. The oxygen carrying capacity can 
be more than three times that of blood (35-70 ml gas/dl at 25 oC) 
and that of CO2 is approximately four times greater than that for 
oxygen (122-255 ml/dl).1 They can be stored at room temperature 
and function as high efficiency heat exchanger.7,8 Most PFCs have 
a surface tension of 12-18 dyne/cm1.62. Although nearly twice as 
dense as water, most PFCs have a similar kinematic viscosity to 
water.9 In general, because PFC liquids are more dense and viscous 
than gas, with slower spreading and higher diffusion coefficients, 
assisted mechanical ventilation techniques are required to support 
pulmonary  gas  exchange  when  the  lung  is  totally  or  partially 
filled with this medium.7 Non-medical uses of PFC include the 
cosmetic industry for their water retention properties, as cooling 
agents and as insulators. In medical applications, besides use as a 
respiratory medium, PFCs are being evaluated as contrast agents 
for computerized tomography and magnetic resonance imaging, as 
sensitizing agents during radiotherapy and as possible intravenous 
oxygen-carrying agents.9,10
The ideal PFC for liquid ventilation should have: (i) a high 
solubility for oxygen and carbon dioxide to maintain gas exchange, 
(ii) a greater density than body fluids so that it descends to the 
dependent regions of the lungs and re-opens the areas of atelectasis, 
(iii) a low surface tension to work like surfactant and improve lung 
compliance,5 (iv) property of being inert and not metabolized and 
eliminated intact by evaporation during exhalation or transpiration 
through the skin,11 (v) sufficient volatility to allow elimination in 
an acceptable time.5 All studies reporting uptake during using 
liquid ventilation have detected very low levels of PFC in the blood 
and tissues. The most current studies report PFC levels of less than 
5.8 mcg/ml of blood. In tissue, the lowest levels were found in the Oman Medical Specialty Board
Oman Medical Journal (2011) Vol. 26, No. 1: 4-9
liver and the highest levels in the lung, followed by fat. Excluding 
lung and fat, tissue levels were less than 250 mg/g of tissue after 24 
hours of liquid ventilation.11
Techniques
The first liquid ventilation with PFCs in animals was performed 
by a chamber above the animal (under the force of gravity), then 
draining the liquid into a chamber below the animal. 9 In another 
method, liquid ventilation was done with an extracorporeal circuit. 
However, the technique and the equipment required were very 
complex. In particular, the extracorporeal circuit had problems 
in development, like malfunction of the expiratory valve.12 PFC is 
instilled at a rate of 1 ml/kg body weight per minute through the 
side port of endotracheal tube without interrupting mechanical 
gas ventilation, maintaining a positive end expiratory pressure of 4 
cm of water. PFC is added as needed to replace liquid lost through 
evaporation  and  to  maintain  the  liquid  FRC  throughout  the 
treatment period. The rate of supplemental administration of PFC 
reflects a loss or gain of functional residual capacity (FRC).13 There 
is a lavage effect during liquid breathing that mobilizes alveolar 
and bronchiolar exudates and fluid to the central airways, where 
they can be removed by suctioning.14 While computer-controlled, 
time-cycled, pressure/volume-limited total liquid ventilators can 
take maximum advantage of these liquids by eliminating the whole 
gas phase in the distressed lung, partial liquid ventilation takes 
advantage of having these liquids in the lung while maintaining 
gas ventilation. The benefits of both partial and total techniques 
have been demonstrated in animal models of neonatal and adult.1
Total Liquid Ventilation (TLV)
 The  lungs  are  filled  with  PFC  to  a  volume  equivalent  to  the
 functional  residual  capacity  (FRC),  approximately  30  ml/kg
 and a “liquid ventilator” is used to generate tidal breathing with
 perfluorocarbon.  Optimal  CO2  clearance  is  achieved  when
 ventilation is performed at a rate of 4-5 breaths/minute. Typical
 tidal volumes are in the 15-20 ml/kg range. One of the advantages
 of TLV is that exudates may be lavages from the airways in the
 setting of respiratory failure. In addition, the distribution of PFC
 within the lungs may be more uniform during TLV.1 Practically
 this  method  was  not  proved  to  be  adequate  for  prolonged
ventilation.15
Partial Liquid Ventitation (PLV) 
 Sometimes called PAGE (PFC associated gas exchange).14 It was
 suggested that the administration of PFC liquid to the lungs may
 function similarly to an artificial surfactant for respiratory distress
 syndrome (RDS) or a lavage medium for certain other types of
 pulmonary  dysfunction.  Several  investigators  have  explored
 tracheal  instillation  of  PFC  liquids  in  combination  with  gas
 ventilation in a variety of neonatal, juvenile, and adult animals as
 well as in preterm human infants and adults who have respiratory
failure.11
Perflubron will be more uniformly distributed if it is given in 
a rotational fashion with alternation between supine and prone 
position  during  incremental  dosing.  This  effect  is  independent 
of the mode of ventilation. There was no relationship between 
improvement  in  oxygenation  and  nondependent  perflubron 
distribution.  Continuous  mechanical  ventilation  and  rotating 
dosing,  both  led  to  an  important  decrease  in  the  oxygenation 
index after a 15 ml/kg dose of perflubron. This information had 
important  effect  on  the  development  of  dosing  strategies  and 
clinical trial design.16
Over the last 40 years, liquid ventilation has been studied in 
various animal models: normal, premature and with lung injury, 
while human studies were focusing mainly on neonates and very 
limited studies done on human adults.
Advantages of liquid ventilation with PFCs
In acute lung injury, liquid ventilation with PFC may improve the 
clinical picture by different mechanisms.
1. Improvement in oxygenation in acute lung injury
In acute lung injury, collapse is mainly in the dependent regions 
of the lungs.17 Because PFCs are dense, they will gravitate to the 
dependent parts of the lungs.17,18 and this will re-open collapsed 
regions of lung, acting as liquid Positive End Expiratory Pressure 
(PEEP). Ventilation/perfusion relationships may also improve.19 
Low-bias flow oscillation (LBFO) with partial liquid ventilation 
(PLV) is a practicable mode of ventilation in a model of acute lung 
injury and is associated with significant preservation of perflubron 
in comparison with high-frequency oscillatory ventilation-PLV. 
The lower evaporative losses during LBFO-PLV were associated 
with improved inflammatory cellular pattern.20
2. Improvement in lung compliance
PLV is thought to improve lung compliance by eliminating the 
air-liquid interface. The exact pattern of distribution of PFCs in 
the alveoli during PLV is not yet known. Unlike surfactant, PFC 
has a constant surface tension. Giving more PFC will therefore 
not reduce the surface tension any more but it will progressively 
open  up  atelectatic  alveoli  by  a  PEEP-like  effect  and  improve 
oxygenation.21  Some  authors  suggest  using  PFCs  by  vapor  or 
aerosol and they can give same effect on lung compliance with less 
side effects.22-24
3. Anti-inflammatory effect
Studies on animals suggest that the use of PFC in liquid ventilation 
may reduce pulmonary inflammation and injury. Perflubron has 
been  shown  to  decrease  cytokine  production  (tumor  necrosis Oman Medical Specialty Board
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factor [TNF] alpha, interleukin [IL] 1, IL 6, IL 8) and chemotaxis 
of activated human alveolar or circulating macrophages.11
4. Alveolar and endobronchial lavage
There is also a lavage effect during liquid breathing that mobilises 
alveolar and bronchiolar exudates and debris to the trachea, where 
they can be removed by suctioning.14
Liquid ventilation in normal lungs
Studies in animals with normal lungs showed worse gas exchange 
with liquid ventilation compared with gas ventilation.25
Classification of clinical applications of liquid ventilation11,14
A.  Classification  for  liquid  ventilation  comprises  of  severe 
respiratory failure due to; a) Hyaline membrane disease, b) Adult 
respiratory distress syndrome, c) Meconium aspiration syndrome, 
d)  Pulmonary  interstitial  emphysema,  and  e)  Congenital 
diaphragmatic hernia.
B. Future applications (experiments done on animals) for liquid 
ventilation include; pulmonary contusion, Inhalation syndrome, 
cystic  fibrosis,  pulmonary  alveolar  proteinosis,  drug  delivery, 
radiographic imaging, temperature control, cellular effect, growth 
of the hypoplastic lung, lung protection during cardiopulmonary 
bypass, lung protection during organ donation, and cancer therapy.
Human neonatal applications
Complications of prematurity are still common despite advances 
in  peri-natal  care  of  preterm  infants.6  The  use  of  surfactant 
replacement  therapy  and  prenatal  steroids  has  substantially 
improved the clinical course of some preterm infants, but not all of 
them respond.11 If new conventional ventilatory interventions fail, 
ECMO is the only alternative method, but is a complex, invasive 
and costly technique and difficult to apply to small infants. PFC 
liquid ventilation is started as a new promising technique to solve 
ventilation problems associated with prematurity.6
The first human trials of PFC liquid breathing were conducted 
in  Philadelphia,  Pennsylvania  in  1989  and  were  initiated  in 
near-death infants who had severe respiratory failure. TLV was 
administered  and  a  gravity-assisted  approach  was  used.  The 
infants  tolerated  the  procedure  and  showed  improvement  in 
several  physiologic  parameters,  including  lung  compliance  and 
gas exchange. Improvement was sustained after liquid ventilation 
was discontinued, but the infants eventually deteriorated. All of 
the infants in these studies ultimately died from their underlying 
respiratory disease.26,27
Leach  et  al.  1996,  reported  a  multi-centric  study  on  13 
premature  infants  with  gestational  age  ranging  from  24  to  34 
weeks  (mean  28  weeks),  birth  weight  ranging  from  640-2000 
grams (mean 1055g), with severe respiratory distress syndrome 
on whom conventional treatment including multiple surfactant 
therapy had failed. PLV was initiated for about 76 hours. Within 
one hour after instillation of PFC, the arterial oxygen tension 
increased by 138% and oxygenation index reduced. The dynamic 
compliance improved during the first hour by more than 60%. It 
was concluded that clinical improvement and survival occurred in 
some infants who were not predicted to survive.15 The newborn 
who  had  CDH  (Congenital  diaphragmatic  hernia)  faces  the 
dilemma  of  pulmonary  hypoplasia  potentially  complicated  by 
surfactant deficiency. PFC liquids have the potential to maximize 
recruitment of the hypoplastic lung while minimizing the surface 
tension  forces  related  to  surfactant  deficiency.11  Pranikoff  and 
associates  reported  results  for  four  patients  who  had  CDH 
and were being managed for up to 5 days on extracorporeal life 
support (ECLS). PLV was performed for up to 6 days with daily 
dosing. Improvement was noticed in gas exchange and pulmonary 
compliance.28  In  a  similar  study,  Greenspan  and  co-workers 
treated  six  term  infants  who  had  respiratory  failure  and  were 
failing  to  improve  while  receiving  ECLS.  They  concluded  that 
the PLV technique appeared to be safe, improved lung function, 
and recruited lung volume in these infants.29 The response of the 
sick term infant to PLV is slower than what typically is observed 
in  the  preterm  infant  who  has  Respiratory  distress  syndrome 
(RDS). The preterm infant often experiences improvement in lung 
compliance and gas exchange within hours of PLV initiation, most 
likely due to reductions in surface tension and volume recruitment. 
Improving lung function in the term infant often requires debris 
removal, which occurs gradually over several days.11 Results from 
other studies suggest that PLV may be safe and efficacious in the 
treatment of paediatric acute respiratory distress.3,28,30,31
Now  there  is  a  hypothesis  which  states  that  immersion  of 
extremely  preterm  infants  in  PFC  liquid  will  allow  optimal 
percutaneous  gas  exchange  to  occur  across  the  skin.  Adding 
some  lung  gas  exchange  with  less  injurious  liquid  ventilation 
(spontaneous or mechanical), the combination of skin and lung gas 
exchange will provide sufficient gas exchange to support life.32
Human adult applications
Hirschl and colleagues treated 10 adults who had ARDS and 
reported a decrease in the physiologic shunt and an increase in 
pulmonary compliance; 50% of the patients survived in their study. 
Based on their clinical experiences, they concluded that PLV may 
be associated with observed improvements in gas exchange and 
pulmonary compliance.33
Bartlett and others presented randomized, controlled trial of 
PLV in 65 adult patients who had acute hypoxemic respiratory 
failure. Forty patients received PLV for 5 days, and 25 patients 
served  as  controls.  Ventilator-free  days  and  mortality  did  not 
differ between the groups, but there was a statistically significant 
improvement in ventilator-free days in subjects treated with PLV 
who were younger than 55 years of age.34Oman Medical Specialty Board
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In another larger trial, 311 patients were randomly assigned 
to receive low dose PLV (lungs filled to the carina in the supine 
position), or high dose PLV (lungs filled to 5 cm caudal to the 
incisors  in  the  supine  position).  There  was  no  difference  in 
mortality among the groups; however, patients who received PLV 
had fewer ventilator-free days and more adverse events including 
pneumothorax, hypoxic episodes, and hypotensive episodes.35
Non-respiratory Applications
This aspect was tested mainly in animals and it represents the 
future hope of liquid ventilation. Latest research initiatives have 
suggested the use of PFC for brain cooling, drug delivery, gene 
transfer or as a contrast agent for ultrasonography of the lung.26,36
PFC liquids are useful contrast media. Because they are inert, 
non-biotransformable,  and  of  varying  radiopacity,  support  gas 
exchange and can be vaporized from the lung, they provide useful 
diagnostic imaging. Radiographic studies of the perflubron-filled 
lungs of animals and humans who had congenital diaphragmatic 
hernia  (CDH)  have  proven  informative  to  show  the  degree  of 
pulmonary hypoplasia.11
Growing  evidence  from  several  laboratories  suggests  that 
intratracheal administration of PFC liquids may reduce pulmonary 
inflammation and injury.11,37
Virtual bronchoscopy is a relatively new technique that adds 
post-processing software to the three-dimensional presentations 
of helical computed tomography and can allow four-dimensional 
imaging of the inside of hollow viscera. Use of the PFC liquid 
perflubron  as  a  bronchographic  contrast  agent  has  enhanced 
markedly the navigation of substantially more distal airways as 
small as 0.8 mm.11
Delivery of drugs to the lungs by PFCs appears promising. The 
high solubility of oxygen and carbon dioxide, low surface tension, 
and their ability to enter collapsed lung regions may permit better 
drug distribution in the diseased lung. PFCs have been studied for 
delivering antibiotics, anaesthetics and vasoactive substances.38-40
Because the lung surface area is large (35 times that of the body 
surface area), the entire cardiac output essentially comes in contact 
with the pulmonary surface, and because the epithelial barrier is 
thin, the lung is an excellent heat exchanger.24 As a result of these 
anatomic and physiologic factors and because of the fact that PFC 
liquids have a higher heat capacity than conventional gas mixtures, 
PFC liquids can be used to warm the lungs and increase core body 
temperature or cool the lungs and decrease core body temperature, 
as required by clinical circumstances.41,42
Another hope of liquid ventilation in neonates is lung protection 
during cardiopulmonary bypass which has been tested in animals. 
Anti-inflammatory effects, avoidance of alveolar collapse, oxygen-
carrying capacity, and surfactant-like properties may protect the 
lung before and during cardiopulmonary bypass.43
The  use  of  liquid  ventilation  in  cancer  therapy  is  also 
investigated.  Liquid  ventilation  may  assist  the  antineoplastic 
effects of radiotherapy and chemotherapy in the lung by inducing 
localized hyperthermia or hyperoxia of the lung surface.9
Finally,  because  perfluorochemicals  have  direct  anti-
inflammatory effect and alveolar stabilizing effect, they have been 
tried as potential useful tools for donor organ preservation prior to 
lung transplantation.44,45
Adverse effects
1.  Pneumothorax  -  Pneumothorax  is  one  of  the  reported 
complications in liquid ventilation.35,46,47 Verbrugge and Lachmann 
proposed a number of reasons for this. If insufficient PEEP is 
applied (from gas or liquid) at end-expiration to support the non-
PFC-filled alveoli, these alveoli will collapse and shear forces could 
cause pneumothorax.47 So even during PLV, using conventional 
PEEP increases oxygenation and may avoid shear stress in non-
dependent lung regions.47,48
2.  Circulatory  impairment  -  Hemodynamic  instability  was 
reported in TLV, where there was an uninterrupted column of PFC 
within the lungs and the tracheobronchial tree (reduced venous 
return). This is not the case with PLV as the column consists of 
liquid and gas (more compressible).49
3.  Lactic acidosis - Although the circulation is maintained during 
liquid  ventilation,  a  metabolic  acidosis  has  been  reported,  the 
reason behind this is still not clear.50
4.  Blocking  of  the  endotracheal  tube  -  Endotracheal  tube 
blocking was reported in many cases due to mucous plugging, 
impairing  gas  exchange  and  requiring  frequent  suctioning  and 
bronchoscopy. This may be due to the exudates in the peripheral 
airways and alveoli which have been displaced into the central 
airways and then removed by suction.46
5.  Carbon  dioxide  elimination  -  In  TLV,  the  problem  of 
ineffective clearance of carbon dioxide was reported, but in PLV 
this problem was less prominent. This is mainly due to the high 
viscosity of PFC compared with gas and a small carbon dioxide 
diffusion coefficient. This can be reduced by appropriate setting of 
the ventilator.48,51
6.  Toxicity  -  Slow  clearance  from  the  body  was  reported  in 
some  studies  about  PFC  metabolism.  Even  after  intravenous 
administration,  elimination  is  mainly  via  the  lung  and  little  if 
any metabolism takes place. PFC particles are taken up by the 
reticulo-endothelial system. Although these substances appear to 
be innocuous and chemically inert, traces have been found three 
years  later  after  a  one  hour  exposure  to  liquid  ventilation.52,53 
However, agents that might be retained in the body for long time 
should be used with caution, even if they appear to do no harm.53
7. Interference with radiographic imaging - PFCs, particularly 
those containing bromide or iodide ions, are radio-opaque. This Oman Medical Specialty Board
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can  interfere  with  subsequent  radiography  and  obscure  some 
structures, which may persist for some weeks.12,54
Future
This subject needs more researches as this field can represent the 
start of new era of clinical use of liquids rather than air to ventilate 
the lung. So, future efforts may involve studying the effects of 
various doses of perflubron and finding more clinical applications 
for perfluorocarbons in general. The possibility of finding new 
substances that can perform same job with more efficacy and less 
side effects should be looked for.
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